NVIDIA Corporation Faces Fresh Slurm Scrutiny After SchedMD Deal Raises AI Control Fears

NVIDIA Corporation Faces Fresh Slurm Scrutiny After SchedMD Deal Raises AI Control Fears

SAN FRANCISCO, April 7, 2026, 04:10 PDT

Nvidia Corp is under the microscope again after a Reuters piece spotlighted worries among AI and supercomputing pros that its acquisition of SchedMD might steer Slurm—the job-scheduling software widely used on large computing clusters—toward favoring Nvidia hardware. In response last week, Nvidia said its customers “benefit from our open source and free software” and pledged ongoing support and upgrades for Slurm for all users. Reuters

Slurm sits at the core of the system, handling the queuing, scheduling, and allocation of workloads across vast arrays of processors in AI and high-performance computing environments. That’s why the issue draws attention. After Nvidia disclosed its agreement in December, it stressed that Slurm would stay both open-source and vendor-neutral. SchedMD CEO Danny Auble described the acquisition as a way to “enhance the development of Slurm,” but emphasized it would remain open source. NVIDIA Blog

Nvidia’s position in the AI spending surge only raises the stakes. For the January quarter, sales soared 94% to $68.13 billion. The chipmaker is now projecting current-quarter revenue to hit $78 billion. Two customers—unnamed in the disclosure—made up 36% of fiscal 2026 sales. CEO Jensen Huang put it bluntly: “This new way of doing computing is not going to go back.” Reuters

With Nvidia’s dominance in AI hardware under scrutiny, customers and competitors are actively searching for other options. Broadcom on Monday announced a long-term deal with Google to build custom AI chips that runs through 2031. Reuters reports demand for Google’s tensor processing units, or TPUs, is picking up as companies look for ways around Nvidia’s more expensive graphics processors.

Back in December, Nvidia framed its SchedMD acquisition as a piece of its wider open-source move, with rivals circling. But as reported by Reuters, CUDA—Nvidia’s own software platform—still stands out as a key chip draw. The bottom line: software control can weigh about as heavily as the hardware.

That’s part of the reason a modest software acquisition has drawn attention well beyond the supercomputing crowd. Late last month, Reuters pointed out that Nvidia’s forward price-to-earnings ratio dropped to its lowest point since early 2019. Investors, the analysis noted, are uncertain whether the heavy AI infrastructure bets from Microsoft, Alphabet, and Amazon will actually translate into revenue and profit at the pace many had been counting on.

The deal isn’t one-dimensional. Nick Patience, who leads AI platforms at Futurum, noted that pulling SchedMD closer could help Nvidia streamline its tech stack. Still, there’s a risk: any step away from Slurm’s vendor-neutral roots might turn into an “optimized barrier” for rivals’ hardware, and that could spark pushback from open-source advocates. Futurum

At the start of trading Tuesday, Nvidia was holding steady near $177.64 a share, putting its market cap around $4.53 trillion. Investors are still letting the company chart its course, though questions hang over whether AI’s next phase depends more on chip speed, software dominance, or a mix.

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR
Previous Story

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire
Next Story

Hologic Buyout Nears Close After Final Approvals in Blackstone-TPG Deal; CEO Steve MacMillan to Retire